Komori
Jeol (6951) · FactAdvanced

Continued Investment in Research and Development

First written in FY2017-Q1. 17 of 33 entries say "Restated". Latest entry: FY2026.

33entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017-Q1 – FY2019-Q3AdvancedFY2022-Q2 – FY2024-Q32016: 220162017: 420172018: 420182019: 420192020: 420202021: 420212022: 220222023: 420232024: 320242025: 120252026: 12026
Same theme, other companies
Continuation of Company-wide R&D Activities and Resource InvestmentA theme 228 companies write about · 1 as a headwind · 237 as a tailwind

51 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 189 companies compared. The sentences above are computed from all 189.Comparing 200 of the theme's 240 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「R&D results by business segment for the fiscal year are as follows, and total R&D expenses were ¥11,405 million.」

    R&D expenses increased from ¥10,264 million in the previous fiscal year to ¥11,405 million, indicating increased investment in R&D.
  2. FY2026-H1Decline in R&D expenditureAnnual report

    「Total R&D expenses for the six-month consolidated period were ¥5,948 million.」

    R&D expenses decreased from ¥6,140 million in the same period of the previous year to ¥5,948 million, but continued to be recorded during the six-month consolidated period.
  3. FY2025-H1AdvancedAnnual report

    「Total R&D expenses for the six-month consolidated period were ¥6,140 million.」

    R&D expenses increased from ¥5,260 million in the same period of the previous year to ¥6,140 million, indicating increased investment in R&D.
  4. FY2024Slight decline in R&D expensesAnnual report

    「Total R&D expenses were ¥10,264 million.」

    R&D expenses decreased from ¥10,391 million in the previous fiscal year to ¥10,264 million, but investment of more than ¥10 billion continued.
  5. FY2024-Q3AdvancedAnnual report

    「Total R&D expenses for the nine-month period ended [current third quarter] were ¥7,673 million.」

    R&D expenses increased from ¥6,805 million in the same period of the previous year to ¥7,673 million, indicating increased investment in R&D.
  6. FY2024-Q2AdvancedAnnual report

    「Total R&D expenses for the six-month period ended [current second quarter] were ¥5,260 million.」

    R&D expenses increased from ¥4,511 million in the same period of the previous year to ¥5,260 million, indicating increased investment in R&D.
  7. FY2024-Q1AdvancedAnnual report

    「Total R&D expenses for the three-month period ended [current first quarter] were ¥2,719 million.」

    R&D expenses of ¥2,719 million were recorded, representing an increase in R&D investment from ¥2,047 million in the same period of the previous year.
  8. FY2023AdvancedAnnual report

    「Total R&D expenses were ¥10,391 million.」

    R&D expenses increased from ¥8,516 million in the previous fiscal year to ¥10,391 million, indicating increased investment in R&D.
  9. FY2023-Q3AdvancedAnnual report

    「Total R&D expenses for the nine-month period ended [current third quarter] were ¥6,805 million.」

    R&D expenses increased from ¥6,194 million in the same period of the previous year to ¥6,805 million, indicating increased investment in R&D.
  10. FY2023-Q2AdvancedAnnual report

    「Total R&D expenses for the six-month period ended [current second quarter] were ¥4,511 million.」

    R&D expenses increased from ¥4,126 million in the previous fiscal year to ¥4,511 million, indicating increased investment in R&D.
  11. FY2022-Q3AdvancedAnnual report

    「Total R&D expenses for the nine-month period ended [current third quarter] were ¥6,194 million.」

    R&D expenses increased from ¥5,782 million in the same period of the previous year to ¥6,194 million, confirming increased investment in R&D.
  12. FY2022-Q2AdvancedAnnual report

    「Total R&D expenses for the six-month period ended [current second quarter] were ¥4,126 million.」

    R&D expenses increased from ¥3,931 million in the same period of the previous year to ¥4,126 million, confirming continued and increased investment in R&D.
  13. FY2022-Q1RestatedAnnual report

    「Total R&D expenses for the three-month period ended [current first quarter] were ¥2,047 million.」

    R&D expenses were recorded again for the quarter, confirming continued investment in R&D activities.
  14. FY2021AdvancedAnnual report

    「R&D results by business segment for the fiscal year are as follows, and total R&D expenses were ¥8,064 million.」

    R&D expenses increased from ¥7,756 million in the previous fiscal year to ¥8,064 million, indicating increased investment in R&D.
  15. FY2021-Q3RestatedAnnual report

    「Total R&D expenses for the nine-month period ended [current third quarter] were ¥5,782 million.」

    R&D expenses were recorded again for the nine-month period ended [current third quarter], confirming continued investment in R&D activities.
  16. FY2021-Q2RestatedAnnual report

    「Total research and development expenses for the first half of the current consolidated cumulative period were ¥3,931 million.」

    Research and development expenses were also recorded for the first half of the current consolidated cumulative period, confirming continued investment in research and development activities.
  17. FY2021-Q1RestatedAnnual report

    「Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥2,088 million.」

    Research and development expenses of ¥2,088 million were recorded again in the first quarter, confirming continued investment in research and development activities.
  18. FY2020AdvancedAnnual report

    「The research and development results by business segment for the current consolidated fiscal year are as follows, and total research and development expenses amounted to ¥7,756 million.」

    Research and development expenses increased from ¥7,184 million in the previous fiscal year to ¥7,756 million, indicating increased investment in research and development.
  19. FY2020-Q3RestatedAnnual report

    「Total research and development expenses for the first nine months of the current consolidated cumulative period were ¥5,596 million.」

    Research and development expenses were also recorded for the first nine months of the current consolidated cumulative period, confirming continued investment in research and development.
  20. FY2020-Q2RestatedAnnual report

    「Total research and development expenses for the first half of the current consolidated cumulative period were ¥3,712 million.」

    Research and development expenses were also recorded for the first half of the current consolidated cumulative period, confirming continued investment in research and development activities.
  21. FY2020-Q1RestatedAnnual report

    「Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥1,857 million.」

    Research and development expenses were recorded again this quarter, confirming continued investment in research and development activities.
  22. FY2019AdvancedAnnual report

    「Total research and development expenses amounted to ¥7,184 million.」

    Research and development expenses increased from ¥6,044 million in the previous fiscal year to ¥7,184 million, indicating increased investment in research and development.
  23. FY2019-Q3RestatedAnnual report

    「Total research and development expenses for the first nine months of the current consolidated cumulative period were ¥5,186 million.」

    The disclosure of ¥5,186 million in research and development expenses confirms the continuation of research and development activities.
  24. FY2019-Q2RestatedAnnual report

    「Total research and development expenses for the first half of the current consolidated cumulative period were ¥3,399 million.」

    The disclosure of ¥3,399 million in research and development expenses confirms the continuation of research and development activities.
  25. FY2019-Q1RestatedAnnual report

    「Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥1,692 million.」

    The disclosure of ¥1,692 million in research and development expenses confirms the continuation of research and development activities.
  26. FY2018RestatedAnnual report

    「Total research and development expenses amounted to ¥6,044 million.」

    Research and development expenses of ¥6,044 million were incurred for the full fiscal year, confirming the continued investment in research and development activities.
  27. FY2018-Q3RestatedAnnual report

    「Total research and development expenses for the first nine months of the current consolidated cumulative period were ¥4,091 million.」

    The disclosure of ¥4,091 million in research and development expenses confirms the continuation of research and development activities.
  28. FY2018-Q2RestatedAnnual report

    「Total research and development expenses for the first half of the current consolidated cumulative period were ¥2,689 million.」

    The disclosure of ¥2,689 million in research and development expenses confirms the continuation of research and development activities.
  29. FY2018-Q1RestatedAnnual report

    「Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥1,351 million.」

    The disclosure of ¥1,351 million in research and development expenses confirms the continuation of research and development activities.
  30. FY2017RestatedAnnual report

    「The research and development results by business segment for the current consolidated fiscal year are as follows, and total research and development expenses amounted to ¥6,129 million.」

    Research and development expenses of ¥6,129 million were recorded for the full fiscal year, reaffirming the company’s continued investment in research and development.
  31. FY2017-Q3RestatedAnnual report

    「Total research and development expenses for the first nine months of the current consolidated cumulative period were ¥5,033 million.」

    The disclosure reiterates that research and development expenses continue to be incurred.
  32. FY2017-Q2RestatedAnnual report

    「Total research and development expenses for the first half of the current consolidated cumulative period were ¥3,635 million.」

    The disclosure reiterates that research and development expenses continue to be incurred.
  33. FY2017-Q1First statedAnnual report

    「Total research and development expenses for the first quarter of the current consolidated cumulative period were ¥1,874 million.」

    The total R&D expenses for the quarter are stated.
Moved together

"Payment of an interim dividend of ¥3.50 per share" moved the same way as this thread, in the same document, in 11 of its 33 moves.

11109988★123456
  1. ★This thread
  2. 1Payment of an interim dividend of ¥3.50 per share11×
  3. 2Declining net assets and equity ratio10×
  4. 3Steady electron microscope inquiries and response to a broad range of applications9×
  5. 4Focus on revenue margin, ROE and equity ratio, among other metrics9×
  6. 5Revenue increased, but operating, ordinary and net income turned negative8×
  7. 6The Scientific and Measuring Instruments Business moved into a segment loss8×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Jeol's next results are scheduled for 2026-11-13. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.